Navigation Links
Roka Bioscience Announces Pricing of Initial Public Offering

WARREN, N.J., July 17, 2014 /PRNewswire/ -- Roka Bioscience, Inc., a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $12.00 per share, before underwriting discounts.  All of the common stock is being offered by Roka Bioscience.  In addition, Roka Bioscience has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the initial public offering price.  The shares are expected to begin trading on the NASDAQ Global Market on July 17, 2014 under the ticker symbol "ROKA".  The offering is expected to close on July 22, 2014, subject to customary closing conditions.    

BofA Merrill Lynch and Leerink Partners are acting as joint book-running managers for the offering. Cowen and Company and Wedbush PacGrow Life Sciences are acting as co-managers.  

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 16, 2014.  When available, copies of the final prospectus relating to this offering may be obtained from BofA Merrill Lynch, Attn: Prospectus Department, 222 Broadway, New York, NY 10038, or via email, at; or from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, via email at, or by phone at (800) 808-7525, ext. 4814.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Roka Bioscience
Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas Detection Assays incorporate our advanced molecular technologies and are performed on our "sample-in, result-out" Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies.  

Steve Sobieski
Chief Financial Officer
(908) 605-4621

Logo -

SOURCE Roka Bioscience, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Avelas Biosciences Closes $6.85 Million in Series B Financing to Advance Real-Time Cancer Visualization Technology to Clinical Proof-of-Concept
2. Sangamo BioSciences Announces Conference Call And Webcast To Discuss Global Collaboration with Biogen Idec to Develop Treatments for Hemoglobinopathies
3. Cardio3 BioSciences, a European biopharmaceutical company, now covered by Edison Investment Research
4. Growth in Bioscience and Pharmaceutical R&D Drives the Market for Gene Expression Reagents, According to a New Trend Report Published by Global Industry Analysts, Inc.
5. Proove Biosciences Successfully Presents Data and Exhibits at the Eastern Pain Association’s Annual Meeting in New York, New York
6. New 2 Hour Educational Learning Labs at MD&M West Will Feature Baxter Bioscience, BMW, Dell, GE Healthcare, Mattel, Northrup Grumman, Starbucks and Other Leading Groups in Design, Manufacturing, Engineering and Automation
7. 5W Public Relations Expands Corporate Practice, Adds PURE Bioscience, Inc. to Client Roster
8. Calithera Biosciences Presents Preclinical Data for CB-839 at the 55th American Society of Hematology Annual Meeting
9. Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting
10. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ambit Biosciences Corporation. - AMBI
11. Neurocrine Biosciences To Present At Deutsche Bank 2013 Biofest And The 25th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
(Date:11/25/2015)... LOS ANGELES and HOLLISTON, Mass. ... Regenerative Technology, Inc. (Nasdaq: HART ), a biotechnology ... announced that CEO Jim McGorry will present ... Tuesday, December 1, 2015 at 2:30 p.m. PT. The ... (link below) for 30 days. Management will also be ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... of Black Aerospace Professionals (OPBAP) has been formalized with the signing of a ... leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... Nov. 24, 2015 Cepheid (NASDAQ: CPHD ... at the following conference, and invited investors to participate ...      Tuesday, December 1, 2015 at 11.00 a.m. ...      Tuesday, December 1, 2015 at 11.00 a.m. ... New York, NY      Tuesday, December ...
Breaking Biology Technology:
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, Inc. ... the development and sale of broadly enabling, pressure cycling ... sciences industry, today announced it has received gross proceeds ... million Private Placement (the "Offering"), increasing the total amount ... or more additional closings are expected in the near ...
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has ... of MIT and Harvard for use of its ... information management tools. The partnership will support the ... biological and chemical research information internally and with ... be used for managing the Institute,s electronic laboratory ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
Breaking Biology News(10 mins):